Insulin lispro-aabc achieved faster onset and earlier glucose-lowering effects than conventional insulin lispro, with trials showing reduced postprandial glucose (PPG) levels without significantly different hypoglycemia risks. This evidence concerns the gene INS and Hypoglycemia.